The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be superior.
TCTMD reported in-depth on the CLOSURE-AF trial after its November 8, 2025, presentation at the AHA Scientific Sessions. The study has now been published in the New England Journal of Medicine. |
NEW ORLEANS, LA—For patients with atrial fibrillation (AF) who are at high risk of both stroke and bleeding, left atrial appendage occlusion (LAAO) isn’t noninferior to standard medical care including anticoagulants, results from the CLOSURE-AF trial show.
The study, as it turned out, went in a different direction than the trialists anticipated.
“I think the result was indeed somewhat unexpected for us, because this is exactly the patient population where we are now…